Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Allergy Clin Immunol Pract ; 7(7): 2262-2269, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30974210

RESUMO

BACKGROUND: Awareness about food allergy and food-induced anaphylaxis (FIA) has increased dramatically over the past decade. It remains unclear, however, whether concordance with guidelines for FIA management has improved over time. OBJECTIVE: Our objective was to describe changes in emergency department (ED) concordance with guidelines for FIA management. METHODS: We analyzed data from 2 multicenter retrospective studies of patients with food-related acute allergic reactions seen in 1 of 17 EDs during 2 time periods: 1999 to 2001 and 2013 to 2015. Visits were identified similarly across years-for example, using International Classification of Diseases, Ninth Revision, Clinical Modification codes 693.1, 995.60, 995.61-995.69, 995.0, and 995.3. Anaphylaxis was defined as an acute allergic reaction with involvement of 2+ organ systems or hypotension. We compared concordance between time periods for 4 guideline recommendations: (1) treatment with epinephrine, (2) discharge prescription for an epinephrine autoinjector (EAI), (3) referral to an allergist/immunologist, and (4) instructions to avoid offending allergen. RESULTS: We compared 290 patients with FIA during 1999 to 2001 and 459 during 2013 to 2015. Any treatment with epinephrine (pre-ED or in the ED) for patients with FIA increased over time (38% vs 56%; P < .001). Prescriptions for EAI at discharge (24% vs 54%; P < .001) and documentation for referral to an allergist/immunologist (14% vs 24%; P = .001) approximately doubled, whereas instructions to avoid the offending allergen did not change significantly (37% vs 43%; P = .08). Receipt of 3+ guideline recommendations remained low but almost quadrupled over the study interval (6% vs 23%; P < .001). CONCLUSIONS: Over the nearly 15-year study interval, we observed clinically and statistically significant increases in ED concordance with epinephrine-related guidelines for FIA. Management gaps remain and interventions to standardize care still appear warranted.


Assuntos
Anafilaxia/terapia , Broncodilatadores/uso terapêutico , Epinefrina/uso terapêutico , Hipersensibilidade Alimentar/terapia , Fidelidade a Diretrizes/tendências , Educação de Pacientes como Assunto/tendências , Encaminhamento e Consulta/tendências , Adolescente , Adulto , Alergia e Imunologia , Anafilaxia/etiologia , Serviços Médicos de Emergência , Serviço Hospitalar de Emergência , Feminino , Alimentos/efeitos adversos , Hipersensibilidade Alimentar/complicações , Humanos , Injeções Intramusculares/instrumentação , Masculino , Guias de Prática Clínica como Assunto , Estudos Retrospectivos , Adulto Jovem
2.
Respir Med ; 140: 21-26, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29957275

RESUMO

BACKGROUND: Maternal prenatal smoking has adverse effects on the growing fetus including those of respiratory nature. Although postnatal smoke exposure is a risk factor for respiratory infections, the effects of prenatal smoking independent of postnatal smoke exposure are less established. We hypothesized that both maternal prenatal smoking, and postnatal smoke exposure are risk factors for severe bronchiolitis during infancy. METHODS: We performed a case-control study of 1353 children born between 1996 and 2011 at a single teaching hospital. Cases were admitted to the same hospital for bronchiolitis during infancy. Maternal prenatal smoking was collected from birth records. Postnatal smoke exposure was collected from review of electronic health records. Multivariable logistic regression was used to evaluate the independent associations of the two smoking variables with severe bronchiolitis. RESULTS: 6% of cases were exposed to maternal prenatal smoking, compared with 4% of controls (P = 0.10). Postnatal smoke exposure was present in the households of 17% of cases compared with 3% of controls (P < 0.001). In a multivariable model with both smoking variables and adjustment for 10 covariates, maternal prenatal smoking was not a significant risk factor for severe bronchiolitis (adjusted OR = 1.02, 95%CI 0.56-1.84). By contrast, postnatal smoke exposure was associated with >300% increased odds (adjusted OR 4.19, 95%CI 2.51-6.98). CONCLUSIONS: Although maternal prenatal smoking has many known adverse effects, it was not associated with increased odds of severe bronchiolitis in either unadjusted or multivariable analyses. Postnatal smoke exposure was a consistently strong risk factor. Our findings support ongoing efforts to decrease infant exposure to ambient smoke.


Assuntos
Bronquiolite/etiologia , Efeitos Tardios da Exposição Pré-Natal , Poluição por Fumaça de Tabaco/efeitos adversos , Estudos de Casos e Controles , Registros Eletrônicos de Saúde , Exposição Ambiental/efeitos adversos , Feminino , Humanos , Lactente , Masculino , Troca Materno-Fetal , Mães/psicologia , Gravidez , Fatores de Risco , Fumar
3.
Ann Allergy Asthma Immunol ; 120(4): 419-423, 2018 04.
Artigo em Inglês | MEDLINE | ID: mdl-29407420

RESUMO

BACKGROUND: Changes in emergency department (ED) concordance with guidelines for the management of stinging insect-induced anaphylaxis (SIIA) are not known. OBJECTIVE: To describe temporal changes in ED concordance with guidelines for the management of SIIAs. METHODS: We analyzed data from 2 multicenter retrospective studies of patients with stinging insect-related acute allergic reactions seen in 1 of 14 North American EDs during 2 periods: 1999 through 2001 and 2013 through 2015. Visits were identified similarly across studies (eg, using International Classification of Diseases, Ninth Revision, Clinical Modification codes 989.5, 995.0, and 995.3). Anaphylaxis was defined as an acute allergic reaction with involvement of at least 2 organ systems or hypotension. We compared concordance between periods with 4 guideline recommendations: (1) treatment with epinephrine, (2) discharge prescription for epinephrine auto-injector, (3) referral to an allergist/immunologist, and (4) instructions to avoid the offending allergen. RESULTS: We compared 182 patients with SIIA during 1999 to 2001 with 204 during 2013 to 2015. Any treatment with epinephrine (before arrival to the ED or in the ED) increased over time (30% vs 49%; P < .001). Prescriptions for epinephrine auto-injector at discharge increased significantly (34% vs 57%; P < .001), whereas documentation of referral to an allergist/immunologist decreased (28% vs 12%; P = .002), and instructions to avoid the offending allergen did not change (23% vs 24%; P = .94). Receipt of at least 3 guideline recommendations increased over time; however, the comparison was not statistically significant (10% vs 16%; P = .15). CONCLUSION: During the nearly 15-year study interval, we observed increased ED concordance with epinephrine-related guideline recommendations for the management of SIIA. Reasons for the decrease in allergy/immunology referrals merit further study.


Assuntos
Anafilaxia/terapia , Serviço Hospitalar de Emergência/normas , Fidelidade a Diretrizes/tendências , Mordeduras e Picadas de Insetos/terapia , Guias de Prática Clínica como Assunto , Adulto , Anafilaxia/etiologia , Animais , Epinefrina/uso terapêutico , Feminino , Humanos , Mordeduras e Picadas de Insetos/complicações , Masculino , Pessoa de Meia-Idade , Encaminhamento e Consulta/tendências , Adulto Jovem
4.
J Allergy Clin Immunol Pract ; 5(3): 616-625.e7, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28483315

RESUMO

Addressing inaccurate penicillin allergies is encouraged as part of antibiotic stewardship in the inpatient setting. However, implementing interventions targeted at the 10% to 15% of inpatients reporting a previous penicillin allergy can pose substantial logistic challenges. We implemented a computerized guideline for patients with reported beta-lactam allergy at 5 hospitals within a single health care system in the Boston area. In this article, we describe our implementation roadmap, including both successes achieved and challenges faced. We explain key implementation steps, including assembling a team, stakeholder engagement, developing or selecting an approach, spreading the change, establishing measures, and measuring impact. The objective was to detail the lessons learned while empowering others to be part of this important, multidisciplinary work to improve the care of patients with reported beta-lactam allergies.


Assuntos
Hipersensibilidade a Drogas/diagnóstico , beta-Lactamas/efeitos adversos , Boston , Humanos , Pacientes Internados , Guias de Prática Clínica como Assunto , Testes Cutâneos , beta-Lactamas/uso terapêutico
6.
J Allergy Clin Immunol Pract ; 5(1): 92-96, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-27523277

RESUMO

BACKGROUND: Severe bronchiolitis (ie, bronchiolitis requiring hospital admission) is thought to markedly increase asthma risk, with 30%-50% developing asthma by age 5 years. To date, studies of this association are small, and most are from outside the United States. OBJECTIVE: The objective of this study was to investigate the association between severe bronchiolitis and risk of asthma in a US birth cohort. METHODS: We studied a cohort nested within the Massachusetts General Hospital Obstetric Maternal Study (MOMS), a prospective cohort of pregnant women enrolled during 1998-2006. Children of mothers enrolled in MOMS were included in the analysis if they received care within our health system (n = 3653). Diagnoses and medications were extracted from the children's electronic health records; we also examined pregnancy and perinatal risk factors collected for the underlying pregnancy study. RESULTS: The birth cohort was 52% male, 49% white, and 105 infants (2.9%) had severe bronchiolitis. Overall, 421 children (11.5%) developed asthma by age 5 years. Among the children with severe bronchiolitis, 27.6% developed asthma by age 5 years. In multivariable logistic regression adjusting for 12 risk factors, severe bronchiolitis remained a strong risk factor for developing asthma by age 5 years (odds ratio 2.57; 95% confidence interval 1.61-4.09). CONCLUSIONS: In a large Boston birth cohort, the frequency of severe bronchiolitis and childhood asthma was similar to published data. Among children with severe bronchiolitis, the risk of developing asthma was lower than prior studies but still high (27.6%). This difference may be due to different study designs, populations, and outcome definitions studied.


Assuntos
Asma/epidemiologia , Bronquiolite/epidemiologia , Hospitalização , Idade de Início , Asma/imunologia , Criança , Pré-Escolar , Estudos de Coortes , Progressão da Doença , Registros Eletrônicos de Saúde , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Gravidez , Prevalência , Estudos Prospectivos , Risco , Estados Unidos/epidemiologia
7.
J Allergy Clin Immunol Pract ; 4(4): 697-704, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27039234

RESUMO

BACKGROUND: Hypersensitivity reactions (HSRs) during the perioperative period are unpredictable and can be life threatening. Prospective studies for the evaluation of perioperative HSRs are lacking, and data on causative agents vary between different studies. OBJECTIVE: The objective of this study was to prospectively determine the success of a comprehensive allergy evaluation plan for patients with HSRs during anesthesia, including identification of a causative agent and outcomes during subsequent anesthesia exposure. METHODS: All patients referred for a perioperative HSR between November 2013 and March 2015, from a Boston teaching hospital, were evaluated using a standardized protocol with skin testing (ST) within 6 months of HSR. Comprehensive allergy evaluation included collection of patient information, including characteristics of HSR during anesthesia. We reviewed the results of ST and/or test doses for all potential causative medications Event-related tryptase levels were reviewed when available. RESULTS: Over 17 months, 25 patients completed the comprehensive allergy evaluation. Fifty-two percent (13 of 25) were female with a median age of 52 (interquartile range 43-66) years. The most frequently observed HSR systems were cutaneous (68%), cardiovascular (64%), and pulmonary (24%). A culprit drug, defined as a positive ST, was identified in 36% (9 of 25) of patients. The most common agent identified was cefazolin (6 of 9). After our comprehensive evaluation and management plan, 7 (7 of 8, 88%) patients tolerated subsequent anesthesia. CONCLUSIONS: Cefazolin was the most commonly identified cause of a perioperative HSR in our study population. Skin testing patients within 6 months of a perioperative HSR may improve the odds of finding a positive result. Tolerance of subsequent anesthesia is generally achieved in patients undergoing our comprehensive evaluation.


Assuntos
Antibacterianos/efeitos adversos , Hipersensibilidade a Drogas/etiologia , Adulto , Idoso , Cefazolina/efeitos adversos , Hipersensibilidade a Drogas/diagnóstico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Período Perioperatório , Testes Cutâneos
9.
Pediatr Allergy Immunol ; 27(4): 413-8, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26766307

RESUMO

BACKGROUND: Infants hospitalized for bronchiolitis (i.e. severe bronchiolitis) are at increased risk of childhood asthma. There are many known risk factors for severe bronchiolitis, including cardiac and pulmonary diseases. Less is known about the association between atopic diseases and risk of severe bronchiolitis. We sought to further examine risk factors for severe bronchiolitis, focusing on atopic dermatitis (AD). METHODS: We conducted a nested cohort study within the Massachusetts General Hospital Obstetric Maternal Study (MOMS), a prospective cohort of pregnant women enrolled during 1998-2006. Children of mothers enrolled in MOMS were included in the analysis if they received care within our health system (n = 5407). Potential risk factors for bronchiolitis and hospitalization data were extracted from the children's electronic health records; we also examined pregnancy and perinatal risk factors collected from the underlying MOMS data. RESULTS: During the first year of life, 125 infants (2.3%) had severe bronchiolitis. Eighteen of these patients had AD; 11 (61%) were diagnosed with AD prior to bronchiolitis hospitalization. In unadjusted analyses, AD was associated with severe bronchiolitis (χ(2) 14.6; p < 0.001). In multivariable analyses adjusting for nine known risk factors for severe bronchiolitis, including demographics, birth season, disposition at birth, cardiac disease, maternal parity, and delivery mode, AD was associated with increased odds of severe bronchiolitis (odds ratio 2.72, 95% confidence interval 1.60-4.63). CONCLUSIONS: Atopic dermatitis is significantly associated with severe bronchiolitis in infancy. The mechanism of the AD-bronchiolitis association is unclear and merits further study; this research may shed light on the pathogenesis of asthma.


Assuntos
Bronquiolite/epidemiologia , Dermatite Atópica/epidemiologia , Adulto , Asma/diagnóstico , Asma/epidemiologia , Boston/epidemiologia , Bronquiolite/diagnóstico , Bronquiolite/terapia , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Dermatite Atópica/diagnóstico , Registros Eletrônicos de Saúde , Feminino , Hospitalização , Humanos , Lactente , Recém-Nascido , Modelos Logísticos , Saúde Materna , Análise Multivariada , Razão de Chances , Gravidez , Prognóstico , Estudos Prospectivos , Medição de Risco , Fatores de Risco , Índice de Gravidade de Doença , Fatores de Tempo , Adulto Jovem
10.
Open Forum Infect Dis ; 2(1): ofv027, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26034776

RESUMO

Validated skin testing is lacking for many drugs, including ceftaroline. The cross-reactivity between ceftaroline and other ß-lactam antibiotics is unknown. We report a case of a pregnant patient with cystic fibrosis and multiple drug allergies who required ceftaroline for methicillin-resistant Staphylococcus aureus pneumonia and underwent an uncomplicated empiric desensitization procedure.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA